# Ecolab Inc.: Form 10-Q for the period ended Jun 30, 2020

- Company: [Ecolab Inc.](/companies/ecl.md) (CIK 31462)
- Form: 10-Q
- Filed: 2020-08-06
- Accepted by EDGAR: Aug 6, 2020, 07:51 ET
- Period: 2020-06-30
- Accession: 0001558370-20-009506
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/31462/000155837020009506/ecl-20200630x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/31462/000155837020009506/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-04-01 to 2020-06-30 | $2.69bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2020-01-01 to 2020-06-30 | $5.71bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2020-04-01 to 2020-06-30 | $1.64bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2020-01-01 to 2020-06-30 | $3.36bn | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months, 2020-04-01 to 2020-06-30 | $788.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2020-01-01 to 2020-06-30 | $1.70bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2020-04-01 to 2020-06-30 | $192.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2020-01-01 to 2020-06-30 | $568.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2020-04-01 to 2020-06-30 | $61.8m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2020-01-01 to 2020-06-30 | $114.4m | us-gaap:InterestExpense |
| Income tax | 3 months, 2020-04-01 to 2020-06-30 | $14.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2020-01-01 to 2020-06-30 | $61.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2020-04-01 to 2020-06-30 | −$2.03bn | us-gaap:ProfitLoss |
| Net income | 6 months, 2020-01-01 to 2020-06-30 | −$1.74bn | us-gaap:ProfitLoss |
| Diluted EPS | 3 months, 2020-04-01 to 2020-06-30 | −$6.98 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2020-01-01 to 2020-06-30 | −$6.00 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2020-04-01 to 2020-06-30 | −$7.06 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2020-01-01 to 2020-06-30 | −$6.07 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2020-04-01 to 2020-06-30 | 291,500,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2020-01-01 to 2020-06-30 | 292,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2020-01-01 to 2020-06-30 | $758.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2020-01-01 to 2020-06-30 | $250.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months, 2020-01-01 to 2020-06-30 | $283.2m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 6 months, 2020-01-01 to 2020-06-30 | $104.7m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2020-06-30 | $1.37bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-06-30 | $5.17bn | us-gaap:AssetsCurrent |
| Total assets | at 2020-06-30 | $18.08bn | us-gaap:Assets |
| Current liabilities | at 2020-06-30 | $3.23bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-06-30 | $12.19bn | us-gaap:Liabilities |
| Current portion of debt | at 2020-06-30 | $534.9m | us-gaap:DebtCurrent |
| Shareholders' equity | at 2020-06-30 | $5.86bn | us-gaap:StockholdersEquity |
| Shares outstanding | at 2020-06-30 | 285,384,775 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 88,917 characters.

The following management discussion and analysis (“MD&A”) provides information we believe is useful in understanding our operating results, cash flows and financial condition. We provide quantitative information about the material sales drivers including the impact of changes in volume and pricing and the effect of acquisitions and changes in foreign currency at the corporate and reportable segment level. We also provide quantitative information regarding special (gains) and charges, discrete tax items and other significant factors we believe are useful for understanding our results. Such quantitative drivers are supported by comments meant to be qualitative in nature. Qualitative factors are generally ordered based on estimated significance.

The MD&A should be read in conjunction with both the unaudited consolidated financial information and related notes included in this Form 10-Q, and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2019. This discussion contains various Non-GAAP Financial Measures and also contains various Forward-Looking Statements within the meaning of the Private Securities Litigation Reform Act of 1995. We refer readers to the statements entitled “Non-GAAP Financial Measures” and “Forward-Looking Statements” located at the end of Part I of this report.

### Comparability of Results

### ChampionX Transaction

On June 3, 2020, the Company completed the previously announced separation of its Upstream Energy business (the “ChampionX business”) in a Reverse Morris Trust transaction (the “Transaction”) through the split-off of ChampionX Holding Inc. (“ChampionX”), formed by Ecolab as a wholly owned subsidiary to hold the ChampionX Business, followed immediately by the merger of ChampionX (the “Merger”) with a wholly owned subsidiary of ChampionX Corporation (f/k/a Apergy Corporation, “Apergy”).

The ChampionX business met the criteria to be reported as discontinued operations because it is a strategic shift in business that has a major effect on the Company's operations and financial results. Therefore, the Company is reporting the historical results of ChampionX, including the results of operations, cash flows, and related assets and liabilities, as discontinued operations for all periods presented herein. Unless otherwise noted, the accompanying MD&A has been revised to reflect the ChampionX business as discontinued operations and all prior year balances have been revised accordingly to reflect continuing operations only.

### Fixed Currency Foreign Exchange Rates

Management evaluates the sales and operating income performance of our non-U.S. dollar functional currency international operations based on fixed currency exchange rates, which eliminate the impact of exchange rate fluctuations on our international operations. Fixed currency amounts are updated annually at the beginning of each year based on translation into U.S. dollars at foreign currency exchange rates established by management, with all periods presented using such rates. Public currency rate data provided within the “Segment Performance” section of this MD&A reflect amounts translated at actual public average rates of exchange prevailing during the corresponding period and is provided for informational purposes only.

### Comparability of Reportable Segments

The ChampionX business was previously recorded in the Global Energy reportable segment and has been reported in discontinued operations. The Downstream operating segment, which was previously included in the Global Energy reportable segment has been aggregated into the Global Industrial reportable segment. The table below reflects the elimination of the Global Energy reportable segment, creation of the Downstream operating segment which is reported in the Global Industrial reportable segment. Also, in the first quarter of 2020, we announced leadership changes which allow for shared oversight and focus on the Healthcare and Life Sciences operating segments and established the Global Healthcare and Life Sciences reportable segment. This segment is comprised of the Healthcare operating segment which was previously aggregated in the Global Institutional reportable segment and the Life Sciences operating segment which was previously aggregated in the Global Industrial reportable segment. Additionally, the Textile Care operating segment being reported in Other, which had previously been aggregated in the Global Industrial reportable segment. The Company made other immaterial changes, including the movement of certain customers and cost allocations between reportable segments.

### Impact of Acquisitions and Divestitures

Acquisition adjusted growth rates exclude the results of our acquired businesses from the first twelve months post acquisition and exclude the results of our divested businesses from the twelve months prior to divestiture. In addition, as part of the separation, the Company also entered into a Master Cross Supply and Product Transfer agreement with ChampionX to provide, receive or transfer certain products for a period up to 36 months. Sales of product to ChampionX under this agreement are recorded in product and equipment sales in the Corporate segment along with the related cost of sales. These sales are removed from the consolidated results as part of the calculation of the impact of acquisitions and divestitures.

### CRITICAL ACCOUNTING ESTIMATES

In our report on Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission on February 28, 2020, we disclosed our Critical Accounting Estimates. The discussion below provides an update to the Critical Accounting Estimates and should be read together with the full list of Critical Accounting Estimates set forth in the aforementioned Form 10-K.

### Goodwill

We had total goodwill of $5.8 billion and $5.6 billion as of June 30, 2020 and December 31, 2019, respectively. Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in a business combination. Our reporting units are our operating segments. We assess goodwill for impairment on an annual basis during the second quarter. If circumstances change significantly, we would complete an interim goodwill assessment of a reporting unit’s goodwill prior to its next annual assessment.

During the second quarter of 2020, the Company completed its annual goodwill impairment assessment for each of its eleven reporting units using quantitative analyses consisting of discounted cash flow approaches that incorporated assumptions regarding future growth rates, terminal values, and discount rates. If the carrying value of a reporting unit is greater than its fair value, the Company will recognize an impairment loss for the amount by which the reporting unit’s carrying value exceeds its fair value, but not to exceed the carrying amount of goodwill assigned to that reporting unit. The Company’s goodwill impairment assessment for 2020 indicated the estimated fair values of each of its reporting units exceeded their carrying amounts by significant margins.

### OVERVIEW OF THE SECOND QUARTER ENDED JUNE 30, 2020

### Sales Performance

When comparing second quarter 2020 against second quarter 2019, sales performance was as follows:

- Reported net sales decreased 15% to $2,686 million, fixed currency sales and acquisition adjusted fixed currency sales decreased 13% and 14%, respectively.
- Fixed currency sales for our Global Industrial segment decreased 2% to $1,476 million, acquisition adjusted fixed currency sales decreased 2%, as modest growth in Food & Beverage was more than offset by lower volumes in the other Industrial businesses.
- Fixed currency sales for our Global Institutional segment decreased 35% to $722 million. Acquisition adjusted fixed currency sales decreased 36%, as very strong growth in Specialty was more than offset by a sharp decline in the in the Institutional businesses, which was impacted by depressed restaurant, lodging and entertainment facility demand due to the COVID-19 pandemic’s shutdown of travel and dining.
- Fixed currency sales for our Global Healthcare and Life Sciences segment increased 22% to $308 million. Acquisition adjusted fixed currency sales also increased 20%, led by strong results due to increased sales due to COVID-19 pandemic in both the Healthcare and Life Sciences businesses.
- Fixed currency sales and acquisition adjusted fixed currency sales for Other sales decreased 19% to $247 million, reflecting the impact of partial and full customer closures along with limited vendor access due to COVID-19 pandemic restrictions.

### Financial Performance

When comparing second quarter 2020 against second quarter 2019, our financial performance was as follows:

- Reported operating income decreased 59% to $192 million. Excluding the impact of special (gains) and charges from both 2020 and 2019 reported results, adjusted operating income decreased 42% and our adjusted fixed currency operating income decreased 39%.
- Net income from continuing operations attributable to Ecolab decreased 62% to $129 million. Excluding the impact of special (gains) and charges and discrete tax items from both 2020 and 2019 reported results, our adjusted net income attributable to Ecolab decreased 50%.
- Reported diluted EPS from continuing operations of $0.44 decreased 63%. Excluding the impact of special (gains) and charges and discrete tax items from both 2020 and 2019 reported results, adjusted diluted EPS decreased 49% to $0.65 in the second quarter of 2020.
- Our reported tax rate was 9.5% during the second quarter of 2020, compared to 20.4% during the second quarter of 2019. Excluding the tax rate impact of special (gains) and charges and discrete tax items from both 2020 and 2019 results, our adjusted tax rate was 20.5% during the second quarter of 2020, compared to 20.2% during the second quarter of 2019.

### RESULTS OF OPERATIONS

### Net Sales

| ​ ​ ​ (millions) | ​ ​ ​ ​ | ​ Second Quarter Ended June 30 2020 | ​ | ​ | ​ ​ | ​ 2019 | ​ | ​ ​ | ​ ​ Change | ​ ​ ​ ​ | ​ ​ ​ ​ | ​ Six Months Ended June 30 2020 | ​ | ​ | ​ ​ | ​ 2019 | ​ | ​ ​ | ​ ​ Change | ​ ​ ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- |
| Product and equipment sales | ​ | **​** | **$2,167.1** | **​** | ​ | ​ | $2,560.0 | ​ | **​** **​** | **​** | ​ | **​** | **$4,591.1** | **​** | ​ | ​ | $4,919.8 | ​ | **​** **​** | ​ |
| Service and lease sales | ​ | **​** | **518.6** | **​** | ​ | ​ | 609.1 | ​ | **​** **​** | **​** | ​ | **​** | **1,115.2** | **​** | ​ | ​ | 1,174.0 | ​ | **​** **​** | ​ |
| Reported GAAP net sales | ​ | **​** | **$2,685.7** | **​** | ​ | ​ | $3,169.1 | ​ | **(15)%** | **​** | ​ | **​** | **$5,706.3** | **​** | ​ | ​ | $6,093.8 | ​ | **(6)%** | ​ |
| Effect of foreign currency translation | ​ |  | **79.3** | **​** | ​ | ​ | 3.1 | ​ | **​** **​** | **​** | ​ |  | **98.5** | **​** | ​ | ​ | (2.7) | ​ | **​** **​** | ​ |
| Non-GAAP fixed currency sales | ​ | **​** | **$2,765.0** | **​** | ​ | ​ | $3,172.2 | ​ | **(13)%** | **​** | ​ | **​** | **$5,804.8** | **​** | ​ | ​ | $6,091.1 | ​ | **(5)%** | ​ |
| ​ | ​ | **​** | **​** | **​** | ​ | ​ | ​ | ​ | **​** ​ | ​ | ​ | **​** | **​** | **​** | ​ | ​ | ​ | ​ | **​** ​ | ​ |

Product and sold equipment revenue is generated from providing cleaning, sanitizing, water and energy products or selling equipment used in combination with specialized products. Service and lease equipment revenue is generated from providing services or leasing equipment to customers. All of our sales are subject to the same economic conditions.

The percentage components of the period-over-period 2020 sales change are shown below:

| ​ ​ ​ ​ ​ ​ ​ ​ (percent) | ​ ​ ​ ​ ​ ​ Second Quarter Ended June 30 2020 | ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ Six Months Ended June 30 2020 |
| --- | ---: | --- | ---: |
| Volume | **(16)%** | **​** | **(7)%** |
| Price changes | **2** **​** | **​** | **2** **​** |
| Acquisition adjusted fixed currency sales change | **(14)** **​** | **​** | **(6)** **​** |
| Acquisitions and divestitures | **1** **​** | **​** | **1** **​** |
| Fixed currency sales change | **(13)** **​** | **​** | **(5)** **​** |
| Foreign currency translation | **(2)** **​** | **​** | **(1)** **​** |
| Reported GAAP net sales change | **(15)%** | **​** | **(6)%** |

Amounts do not necessarily sum due to rounding.

### Cost of Sales (“COS”) and Gross Profit Margin

| ​ ​ ​ ​ ​ (millions/percent) | ​ Second Quarter Ended June 30 2020 COS | ​ | ​ | ​ ​ | ​ ​ Gross Margin | ​ ​ ​ ​ | ​ 2019 COS | ​ | ​ | ​ ​ | ​ ​ Gross Margin | ​ ​ ​ ​ ​ ​ | ​ Six Months Ended June 30 2020 COS | ​ | ​ | ​ ​ | ​ ​ Gross Margin | ​ ​ ​ ​ | ​ 2019 COS | ​ | ​ | ​ ​ | ​ ​ Gross Margin |
| --- | --- | ---: | --- | --- | --- | --- | --- | ---: | --- | --- | --- | --- | --- | ---: | --- | --- | --- | --- | --- | ---: | --- | --- | --- |
| Product and equipment cost of sales | ​ | **$1,301.5** | ​ | ​ | **​** **​** | ​ | ​ | $1,422.1 | ​ | ​ | ​ ​ | ​ | ​ | **$2,666.2** | ​ | ​ | **​** **​** | ​ | ​ | $2,762.7 | ​ | ​ | ​ ​ |
| Service and lease cost of sales | ​ | **334.2** | ​ | ​ | **​** **​** | ​ | ​ | 358.2 | ​ | ​ | ​ ​ | ​ | ​ | **689.7** | ​ | ​ | **​** **​** | ​ | ​ | 693.1 | ​ | ​ | ​ ​ |
| Reported GAAP COS and gross margin | ​ | **$1,635.7** | ​ | ​ | **39.1%** | ​ | ​ | $1,780.3 | ​ | ​ | 43.8% | ​ | ​ | **$3,355.9** | ​ | ​ | **41.2%** | ​ | ​ | $3,455.8 | ​ | ​ | 43.3% |
| Special (gains) and charges | ​ | **27.0** | ​ |  | **​** **​** | ​ | ​ | 7.8 | ​ |  | ​ ​ | ​ | ​ | **36.1** | ​ |  | **​** **​** | ​ | ​ | 11.4 | ​ |  | ​ ​ |
| Non-GAAP adjusted COS and gross margin | **​** | **$1,608.7** | ​ | ​ | **40.1%** | ​ | ​ | $1,772.5 | ​ | ​ | 44.1% | ​ | **​** | **$3,319.8** | ​ | ​ | **41.8%** | ​ | ​ | $3,444.4 | ​ | ​ | 43.5% |

Our COS and corresponding gross profit margin (“gross margin”) are shown in the table above. Gross margin is defined as net sales less cost of sales divided by net sales.

Our reported gross margin was 39.1% and 43.8% for the second quarter of 2020 and 2019, respectively. Our reported gross margin for the first six months of 2020 and 2019 was 41.2 and 43.3%, respectively. Special (gains) and charges included in items impacting COS are shown within the “Special (Gains) and Charges” table on page 39.

Excluding the impact of special (gains) and charges within COS, second quarter 2020 adjusted gross margin was 40.1% and our adjusted gross margin for the first six months of 2020 was 41.8%. These percentages compared against a second quarter 2019 adjusted gross margin of 44.1% and an adjusted gross margin of 43.5% for the first six months of 2019.

Our adjusted gross margin decreased when comparing the second quarter of 2020 against the second quarter of 2019, and decreased compared to the first six months of 2020 and 2019, which was driven primarily by lower volume and unfavorable business mix which more than offset the benefits of pricing, cost savings actions and lower delivered product costs.

### Selling, General and Administrative Expense

Selling, general and administrative (“SG&A”) expenses as a percentage of sales were 29.4% and 29.7% for the second quarter and first six months of 2020, respectively, compared to 28.4% and 29.5% for the second quarter and first six months of 2019, respectively. The increased SG&A ratio to sales in the second quarter of 2020 was driven primarily by lower sales and increased bad debt expense, which more than offset the benefits from lower incentive compensation, discretionary expense and cost savings.

### Special (Gains) and Charges

Special (gains) and charges reported on the Consolidated Statement of Income include the following items:

| ​ ​ ​ ​ (millions) Cost of sales | ​ ​ ​ ​ ​ | ​ ​ Second Quarter Ended June 30 2020 ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ ​ | ​ ​ 2019 ​ | ​ ​ ​ | ​ ​ ​ ​ ​ | ​ ​ Six Months Ended June 30 2020 ​ | ​ ​ ​ | ​ ​ ​ | ​ ​ ​ ​ | ​ ​ 2019 ​ | ​ ​ ​ | ​ ​ ​ ​ ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | ---: | --- | --- | --- | ---: | --- |
| Restructuring activities | ​ | **​** | **$2.6** | ​ | ​ | ​ | $6.5 | ​ | **​** | **$5.6** | ​ | ​ |  | $9.9 | ​ |
| Acquisition and integration activities | ​ | **​** | **2.2** | ​ | ​ | ​ | 1.3 | ​ | ​ | **2.6** | ​ | ​ | ​ | 1.5 | ​ |
| Other | ​ | **​** | **22.2** | ​ | ​ | ​ | - | ​ | **​** | **27.9** | ​ | ​ | ​ | - | ​ |
| Cost of sales subtotal | ​ | **​** | **27.0** | ​ | ​ | ​ | 7.8 | ​ | **​** | **36.1** | ​ | ​ |  | 11.4 | ​ |
| ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ | ​ |
| Special (gains) and charges | ​ | **​** | **​** | ​ | ​ | ​ | ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ | ​ |
| Restructuring activities | ​ | **​** | **0.3** | ​ | ​ | ​ | 19.8 | ​ | **​** | **4.5** | ​ | ​ |  | 50.9 | ​ |
| Acquisition and integration activities | ​ | **​** | **(2.6)** | ​ | ​ | ​ | 0.4 | ​ | **​** | **2.8** | ​ | ​ | ​ | 2.9 | ​ |
| Disposal and impairment activities | ​ | **​** | **44.7** | ​ | ​ | ​ | - | ​ | **​** | **45.9** | ​ | ​ | ​ | - | ​ |
| Other | ​ | **​** | **27.0** | ​ | ​ | ​ | 4.2 | ​ | **​** | **32.1** | ​ | ​ |  | 10.1 | ​ |
| Special (gains) and charges subtotal | ​ | **​** | **69.4** | ​ | ​ | ​ | 24.4 | ​ | **​** | **85.3** | ​ | ​ |  | 63.9 | ​ |
| ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ | ​ |
| Operating income subtotal | ​ | **​** | **96.4** | ​ | ​ | ​ | 32.2 | ​ | **​** | **121.4** | ​ | ​ | ​ | 75.3 | ​ |
| ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ | ​ |
| Interest expense, net | ​ | **​** | **0.7** | ​ | ​ | ​ | - | ​ | **​** | **0.7** | ​ | ​ | ​ | 0.2 | ​ |
| Total special (gains) and charges | ​ | **​** | **$97.1** | **​** | ​ | ​ | $32.2 | ​ | **​** | **$122.1** | **​** | **​** | ​ | $75.5 | ​ |

For segment reporting purposes, special (gains) and charges are not allocated to reportable segments, which is consistent with our internal management reporting.

### Restructuring activities

Restructuring activities are primarily related to Accelerate 2020 (described below). These activities have been included as a component of cost of sales and special (gains) and charges on the Consolidated Statement of Income. Restructuring liabilities have been classified as a component of other current and other noncurrent liabilities on the Consolidated Balance Sheet. Restructuring charges directly related to the ChampionX business have been recorded as discontinued operations, refer to Note 4.

#### Accelerate 2020

During the third quarter of 2018, we formally commenced a restructuring plan Accelerate 2020 (“the Plan”), to leverage technology and system investments and organizational changes. During the second quarter of 2019, we raised our goals for the Plan to further simplify and automate processes and tasks, reduce complexity and management layers, consolidated facilitates and focus on key long-term growth areas by further leveraging technology and structural improvements. We expect that the restructuring activities will be completed by the end of 2020, with total anticipated costs of $215 million ($165 million after tax), or $0.56 per diluted share, over this period of time. Costs are expected to be primarily cash expenditures for severance costs and some facility closure costs relating to team reorganizations. Actual costs may vary from these estimates depending on actions taken.

We recorded restructuring charges of $2.8 million ($2.4 million after tax), or $0.01 per diluted share and $9.1 million ($7.7 million after tax), or $0.03 per diluted share in the second quarter and first six months of 2020, respectively. The liability related to the Plan was $72.5 million as of the end of the second quarter of 2020. We have recorded $206.5 million ($158.6 million after tax), or $0.55 per diluted share, of cumulative restructuring charges under the Plan. The majority of the pretax charges represent net cash expenditures which are expected to be paid over a period of a few months to several quarters and continues to be funded from operating activities. Cash payments during 2020 related to Accelerate 2020 were $31.8 million.

The Plan has delivered $151 million of cumulative cost savings with estimated annual cost savings of $270 million in continuing operations by 2021.

#### Other Restructuring Activities

During the second quarter and first six months of 2020, we incurred restructuring charges of $0.1 million (less than $0.1 million after tax), or less than $0.01 per diluted share and $1.0 million ($0.6 million after tax), or less than $0.01 per diluted share, respectively, related to an immaterial restructuring plan. The charges primarily related to severance. Prior to 2018, we engaged in a number of restructuring plans. During the second quarter and first six months of 2020 and 2019, net restructuring charges related to prior year plans were minimal. The restructuring liability balance for all plans commencing prior to 2018 was $6.1 million and $7.7 million as of June 30, 2020 and December 31, 2019, respectively. The reduction in liability was driven primarily by severance payments. The remaining liability is expected to be paid over a period of a few months to several quarters and will continue to be funded from operating activities.

Cash payments during 2020 related to all other restructuring plans excluding Accelerate 2020 were $2.4 million.

### Acquisition and integration related costs

Acquisition and integration costs reported in special (gains) and charges on the Consolidated Statement of Income include ($2.6) million ($1.7 million after tax) or $0.01 per diluted share, and $2.8 million ($2.1 million after tax) or $0.01 per diluted share, in the second quarter and first six months of 2020, respectively. Charges are related to Copal Invest NV, including its primary operating entity CID Lines (collectively, “CID Lines”), Bioquell PLC (“Bioquell”) and the Laboratoires Anios (“Anios”) acquisitions and consist of integration costs, advisory and legal fees, and hedge activity. Acquisition and integration costs reported in product and equipment cost of sales of $2.6 million ($1.9 million after tax) or $0.01 per diluted share in the first six months of 2020, on the Consolidated Statement of Income relate to the recognition of fair value step-up in the CID Lines inventory, severance and the closure of a facility. We also incurred $0.7 million ($0.5 million after tax) or less than $0.01 per diluted share, of interest expense in the first six months of 2020.

Acquisition and integration costs reported in special (gains) and charges on the Consolidated Statement of Income include $0.4 million ($0.3 million after tax) or less than $0.01 per diluted share, and $2.9 million ($2.1 million after tax) or less than $0.01 per diluted share, in the second quarter and first six months of 2019, respectively. Charges are related to Bioquell and the Anios acquisitions and consist of integration costs, advisory and legal fees. Acquisition and integration costs reported in product and equipment cost of sales of $1.5 million ($1.1 million after tax) or less than $0.01 per diluted share, on the Consolidated Statement of Income in the first six months of 2019 relate to the recognition of fair value step-up in the Bioquell inventory. We also incurred $0.2 million ($0.1 million after tax) or less than $0.01 per diluted share, of interest expense in the first six months of 2019.

### Disposal and impairment charges

Disposal and impairment charges reported in special (gains) and charges on the Consolidated Statement of Income include $44.7 million ($44.1 million after tax) or $0.15 per diluted share, and $45.9 million ($45.0 million after tax) or $0.15 per diluted share in the second quarter and first six months of 2020, respectively. During the second quarter of 2020, we recorded a $28.6 million ($28.6 million after tax) or $0.10 per diluted share impairment for a minority equity method investment due to the COVID-19 impact on the economic environment and the liquidity of the minority equity method investment. In addition, we recorded charges of $16.1 million ($15.5 million after tax) or $0.06 per diluted share related to the disposal of Holchem Group Limited (“Holchem”) for the loss on sale and related transaction fees. Further information related to the our disposal is included in Note 3.

### Other

During the second quarter and first six months of 2020, we recorded charges of $26.5 million to protect the pay for certain employees directly impacted by the COVID-19 pandemic. In addition, we received subsidies and government assistance, which was recorded as a special (gain) of $9.4 million. The specific COVID-19 pandemic charges of $1.1 million are recorded in product and equipment sales on the Consolidated Statement of Income, $5.8 million in service and lease sales on the Consolidated Statement of Income and $10.2 million in special (gains) and charges on the Consolidated Statement of Income. After tax-charges related to COVID-19 pandemic were $13.2 million or $0.05 per diluted share during the second quarter and first six months of 2020.

During the second quarter and first six months of 2020, we recorded special charges of $15.3 million ($10.5 million after tax) or $0.04 per diluted share and $21.0 million ($14.3 million after tax) or $0.05 per diluted share, respectively, recorded in product and equipment cost of sales on the Consolidated Statement of Income primarily related to a Healthcare product recall in Europe.

Other special charges of $16.8 million ($12.6 million after tax) or $0.04 per diluted share and $21.9 million ($16.5 million after tax) or $0.06 per diluted share recorded in the second quarter and first six months of 2020, respectively, relate primarily to a specific legal reserve and related legal charges which are recorded in special (gains) and charges on the Consolidated Statement of Income.

During the second quarter and first six months of 2019, we recorded other special charges of $4.1 million ($3.1 million after tax) or $0.01 per diluted share and $10.0 million ($7.5 million after tax) or $0.03 per diluted share, respectively, which primarily related to legal charges.

### Operating Income and Operating Income Margin

| ​ ​ ​ ​ (millions) | ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Second Quarter Ended June 30 2020 2019 ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30 2020 2019 ​ | ​ ​ ​ ​ Change |
| --- | --- | --- | --- | --- | --- | --- |
| Reported GAAP operating income | ​ | **​** **$192.0** **​** ​ ​ $464.4 ​ | **(59)%** | ​ | **​** **$568.2** **​** ​ ​ $778.0 ​ | **(27)%** |
| Special (gains) and charges | ​ | **96.4** **​** ​ 32.2 ​ | ​ ​ | ​ | **121.4** **​** ​ 75.3 ​ | ​ ​ |
| Non-GAAP adjusted operating income | ​ | **288.4** **​** ​ 496.6 ​ | **(42)%** | ​ | **689.6** **​** ​ 853.3 ​ | **(19)%** |
| Effect of foreign currency translation | ​ | **14.2** **​** ​ 1.2 ​ | ​ ​ | ​ | **16.9** **​** ​ 0.9 ​ | ​ ​ |
| Non-GAAP adjusted fixed currency operating income | ​ | **​** **$302.6** **​** ​ ​ $497.8 ​ | **(39)%** | ​ | **​** **$706.5** **​** ​ ​ $854.2 ​ | **(17)%** |
| ​ | ​ | ​ **​** **​** ​ ​ ​ ​ | ​ ​ | ​ | ​ **​** **​** ​ ​ ​ ​ | ​ ​ |
| ​ | ​ | Second Quarter Ended | ​ ​ | ​ | Six Months Ended | ​ ​ |
| ​ | ​ | June 30 | ​ ​ | ​ | June 30 | ​ ​ |
| (percent) | ​ | **2020** ​ 2019 | ​ ​ | ​ | **2020** ​ 2019 | ​ ​ |
| Reported GAAP operating income margin | ​ | **​** **7.1%** ​ ​ 14.7% | ​ ​ | ​ | **​** **10.0%** ​ ​ 12.8% | ​ ​ |
| Non-GAAP adjusted operating income margin | ​ | **​** **10.7%** ​ ​ 15.7% | ​ ​ | ​ | **​** **12.1%** ​ ​ 14.0% | ​ ​ |
| Non-GAAP adjusted fixed currency operating income margin | ​ | **​** **10.9%** ​ ​ 15.7% | ​ ​ | ​ | **​** **12.2%** ​ ​ 14.0% | ​ ​ |

Our operating income and corresponding operating income margin are shown in the previous tables. Operating income margin is defined as operating income divided by net sales.

Our reported operating income decreased 59% and 27% in the second quarter and first six months of 2020, respectively, versus the comparable periods of 2019. Our reported operating income for 2020 and 2019 was impacted by special (gains) and charges; excluding the impact of special (gains) and charges from 2020 and 2019 reported results, our adjusted operating income decreased 42% and 19% in the second quarter and first six months of 2020, respectively.

As shown in the previous table, foreign currency had a 3% and 2% impact on adjusted operating income growth for the second quarter and first six months of 2020, respectively. Foreign currency had a 4% impact on adjusted operating income growth for the second quarter and first six months of 2019.

### Other (Income) Expense

Other income was $15.1 million and $20.9 million in the second quarter of 2020 and 2019, respectively. Other income was $30.5 million and $42.1 million in the first six months of 2020 and 2019, respectively. Other income decreased due to the return on pension assets and non-service costs of our pension obligations.

### Interest Expense, Net

| ​ ​ ​ (millions) | ​ ​ ​ ​ | ​ Second Quarter Ended June 30 2020 | ​ | ​ | ​ | ​ 2019 | ​ | ​ ​ ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ | ​ Six Months Ended June 30 2020 | ​ | ​ | ​ | ​ 2019 | ​ | ​ ​ ​ | ​ ​ ​ ​ Change |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | ---: | --- | --- | ---: | --- | --- | --- | ---: | --- | ---: |
| Reported GAAP interest expense, net | ​ | **​** | **$58.7** | **​** | ​ | ​ | $49.2 | ​ | **19%** | ​ | **​** | **$107.0** | **​** | ​ | ​ | $98.5 | ​ | **9%** |
| Special (gains) and charges | ​ | **​** | **0.7** | **​** | ​ |  | - | ​ | ​ ​ | ​ | **​** | **0.7** | **​** | ​ |  | 0.2 | ​ | ​ ​ |
| Non-GAAP adjusted interest expense, net | ​ | **​** | **$58.0** | **​** | ​ | ​ | $49.2 | ​ | **18%** | ​ | **​** | **$106.3** | **​** | ​ | ​ | $98.3 | ​ | **8%** |

Reported net interest expense was $58.7 million and $49.2 million in the second quarter of 2020 and 2019, respectively. Reported net interest expense was $107.0 million and $98.5 million in the first six months of 2020 and 2019, respectively. The increase in net interest expense when comparing 2020 against 2019 was driven primarily by higher outstanding debt.

### Provision for Income Taxes

The following table provides a summary of our tax rate:

| ​ ​ ​ (percent) ​ | ​ ​ ​ ​ | ​ ​ Second Quarter Ended June 30 2020 ​ ​ | ​ ​ ​ | ​ ​ 2019 ​ ​ | ​ ​ ​ ​ | ​ ​ Six Months Ended June 30 2020 ​ ​ | ​ ​ ​ | ​ ​ 2019 ​ ​ |
| --- | --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| Reported GAAP tax rate | **​** | **9.5%** | **​** | 20.4% | **​** | 12.4% | **​** | 16.4% |
| Tax rate impact of: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Special (gains) and charges |  | **1.9** **​** | **​** | 0.1 ​ | **​** | **0.9** **​** | **​** | 0.8 |
| Discrete tax items |  | **9.1** **​** | **​** | (0.3) ​ | **​** | **7.2** **​** | **​** | 3.3 |
| Non-GAAP adjusted tax rate |  | **20.5%** | **​** | 20.2% |  | **20.5%** | **​** | 20.5% |

Our reported tax rate was 9.5% and 20.4% for the second quarter of 2020 and 2019, respectively, and 12.4% and 16.4% for the first six months of 2020 and 2019, respectively. The change in our tax rate for the second quarter and first six months of 2020 versus the comparable period of 2019 was driven primarily by discrete tax items and special (gains) and charges. The tax impact of special (gains) and charges and discrete tax items will likely continue to impact comparability of our reported tax rate in the future as amounts included in special (gains) and charges are derived from tax jurisdictions with rates that vary from our effective tax rate, and discrete tax items are not necessarily consistent across periods. Further information related to special (gains) and charges is included in Note 2. Our tax rate is based on our interpretations of existing tax rules; potential future guidance including regulations not yet issued could impact the future tax rate.

We recognized total net tax benefits related to discrete tax items of $22.5 million and $44.4 million in the second quarter and first six months of 2020, respectively. Share-based compensation excess tax benefit contributed $23.3 million and $45.6 million in the second quarter and first six months of 2020, respectively. Additionally, we recognized expense of $0.6 million and $4.5 million primarily related to the filing of prior year foreign tax returns and other income tax adjustments in the second quarter and first six months of 2020, respectively. The remaining discrete expense of $0.2 million and benefit of $3.3 million was due to the accrual of interest on uncertain tax positions offset by reserve released during the quarter and the first six months of 2020, respectively.

We recognized total net tax expense related to discrete tax items of $1.2 million and net benefits of $26.2 million in the second quarter and first six months of 2019, respectively. Share-based compensation excess tax benefit contributed $13.0 million and $31.5 million in the second quarter and first six months of 2019, respectively. We also recognized expense of $6.2 million and $1.1 million in the second quarter and first six months of 2019, respectively, due to issuance of technical guidance during the quarter related to the one-time transition tax imposed by the Tax Cuts and Jobs Act (the “Act”). Additionally, we recognized expense of $10.2 million in the second quarter and first six months of 2019 due to issuance of technical guidance during the quarter related to the calculation of foreign tax credits. The remaining discrete benefit was primarily related to changes in tax rates in non-U.S. jurisdictions.

### Net Income from Continuing Operations Attributable to Ecolab

| ​ ​ ​ (millions) | ​ ​ ​ | ​ Second Quarter Ended June 30 2020 | ​ | ​ | ​ | ​ 2019 | ​ | ​ | ​ ​ Change | ​ ​ ​ | ​ Six Months Ended June 30 2020 | ​ | ​ | ​ | ​ 2019 | ​ | ​ | ​ ​ Change |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- |
| Reported GAAP net income from continuing operations attributable to Ecolab | **​** | **​** | **$128.9** | **​** | ​ | ​ | $343.4 | **​** | **(62)%** | **​** | **​** | **$420.9** | **​** | ​ | ​ | $595.0 | **​** | **(29)%** |
| Adjustments: | ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ | **​** ​ | ​ | ​ | **​** | **​** | ​ | ​ | ​ | ​ | **​** ​ |
| Special (gains) and charges, after tax | ​ |  | **83.3** | **​** | ​ | ​ | 25.2 | ​ | **​** ​ | ​ | **​** | **101.8** | **​** | ​ | ​ | 57.1 | ​ | **​** ​ |
| Discrete tax net expense (benefit) | ​ |  | **(22.5)** | **​** | ​ | ​ | 1.2 | ​ | **​** ​ | ​ | **​** | **(44.4)** | **​** | ​ | ​ | (26.2) | ​ | **​** ​ |
| Non-GAAP adjusted net income from continuing operations attributable to Ecolab | ​ | **​** | **$189.7** | **​** | ​ | ​ | $369.8 | ​ | **(49)%** | ​ | **​** | **$478.3** | **​** | ​ | ​ | $625.9 | ​ | **(24)%** |

### Diluted EPS from Continuing Operations

| ​ ​ ​ (dollars) | ​ ​ ​ | ​ Second Quarter Ended June 30 2020 | ​ | ​ | ​ | ​ 2019 | ​ | ​ | ​ ​ Change | ​ ​ ​ | ​ Six Months Ended June 30 2020 | ​ | ​ | ​ | ​ 2019 | ​ | ​ | ​ ​ Change |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- |
| Reported GAAP diluted EPS from continuing operations | **​** | **​** | **$0.44** | **​** | ​ | ​ | $ 1.18 | **​** | **(63)%** | **​** | **​** | **$1.44** | **​** | ​ | ​ | $ 2.04 | **​** | **(29)%** |
| Adjustments: | ​ | ​ | **​** | ​ | ​ | ​ | ​ | ​ | ​ ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ ​ |
| Special (gains) and charges | **​** |  | **0.29** | **​** | ​ | ​ | 0.09 | ​ | ​ ​ | **​** | **​** | **0.35** | **​** | ​ | ​ | 0.20 | ​ | ​ ​ |
| Discrete tax net expense (benefit) | ​ |  | **(0.08)** | **​** | ​ | ​ | - | ​ | ​ ​ | ​ | **​** | **(0.15)** | **​** | ​ | ​ | (0.09) | ​ | ​ ​ |
| Non-GAAP adjusted diluted EPS from continuing operations | ​ | **​** | **$0.65** | **​** | ​ | ​ | $ 1.27 | ​ | **(49)%** | ​ | **​** | **$1.64** | **​** | ​ | ​ | $ 2.14 | ​ | **(23)%** |

Per share amounts in the above tables do not necessary sum due to rounding.

Currency translation had an unfavorable impact of approximately $0.04 and $0.05 per share on diluted EPS for the second quarter and first six months of 2020, respectively, when compared to the comparable periods of 2019.

### DISCONTINUED OPERATIONS

The ChampionX business met the criteria to be reported as discontinued operations and the historical results of ChampionX, including the results of operations, are reported as discontinued operations for all periods presented. The net loss from discontinued operations, net of tax was $2,163.9 million and $2,172.5 million in the second quarter and first six months of 2020, respectively. Net income from discontinued operations, net of tax was $25.2 million and $70.1 million in the second quarter and first six months of 2019, respectively.

In connection with the ChampionX Separation, Ecolab received cash of $527 million and $1,051 million of non-cash consideration of approximately 5.0 million shares of Ecolab common stock for the ChampionX net assets, including CTA, of $3,717, resulting in a loss.

Special (gains) and charges of $2,186.1 million and $2,222.7 million in the second quarter and first six months of 2020, respectively primarily relate to the loss on separation, transaction fees, and other professional fees incurred to support the Transaction. Special (gains) and charges of $20.8 million and $20.3 million in the second quarter and first six months of 2019, respectively, primarily relate to restructuring charges and transaction fees and other professional fees incurred to support the Transaction.

### SEGMENT PERFORMANCE

The non-U.S. dollar functional international amounts included within our reportable segments are based on translation into U.S. dollars at the fixed currency exchange rates used by management for 2020. The difference between the fixed currency exchange rates and the actual currency exchange rates is reported as “effect of foreign currency translation” in the following tables. All other accounting policies of the reportable segments are consistent with U.S. GAAP and the accounting policies described in Note 2 of our Annual Report on Form 10-K for the year ended December 31, 2019. Additional information about our reportable segments is included in Note 16.

Fixed currency net sales and operating income for the second quarter and first six months of 2020 and 2019 for our reportable segments are shown in the following tables.

| ​ Net Sales ​ (millions) | ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Second Quarter Ended June 30 2020 2019 ​ ​ Change | ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30 2020 2019 ​ ​ Change |
| --- | --- | --- | --- | --- |
| Global Industrial | **​** | **​** **$1,475.6** **​** ​ $1,500.7 ​ **(2)%** | **​** | **​** **$2,919.2** **​** ​ $2,897.7 ​ **1%** |
| Global Institutional |  | **​** **722.4** **​** ​ 1,112.5 ​ ​ **(35)** ​ |  | **​** **1,794.5** **​** ​ 2,132.7 ​ ​ **(16)** ​ |
| Global Healthcare and Life Sciences | **​** | **​** **307.6** **​** ​ ​ 252.8 ​ ​ **22** ​ | **​** | **​** **554.1** **​** ​ ​ 479.8 ​ ​ **15** ​ |
| Other | **​** | **​** **247.1** **​** ​ ​ 306.2 ​ ​ **(19)** ​ | **​** | **​** **524.7** **​** ​ ​ 580.9 ​ ​ **(10)** ​ |
| Corporate |  | **​** **12.3** **​** ​ - ​ ​ **100** ​ |  | **​** **12.3** **​** ​ - ​ ​ **100** ​ |
| Subtotal at fixed currency |  | **​** **2,765.0** **​** ​ 3,172.2 ​ ​ **(13)** ​ |  | **​** **5,804.8** **​** ​ 6,091.1 ​ ​ **(5)** ​ |
| Effect of foreign currency translation |  | **​** **(79.3)** **​** ​ (3.1) ​ ​ **​** ​ |  | **​** **(98.5)** **​** ​ 2.7 ​ ​ **​** ​ |
| Consolidated reported GAAP net sales |  | **​** **$2,685.7** **​** ​ ​ $3,169.1 ​ ​ **(15)%** |  | **​** **$5,706.3** **​** ​ ​ $6,093.8 ​ ​ **(6)%** |
| ​ | ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ | ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
| **Operating Income** | **​** | Second Quarter Ended | ​ | Six Months Ended |
| ​ | **​** | June 30 | ​ | June 30 |
| (millions) | ​ | **2020** 2019 ​ ​ **Change** | ​ | **2020** 2019 ​ ​ **Change** |
| Global Industrial |  | **$283.0** **​** ​ $220.9 **​** **28%** | ​ | **$489.6** **​** ​ $382.3 **​** **28%** |
| Global Institutional |  | **​** **(37.0)** **​** ​ 234.4 **​** **(116)** ​ | ​ | **​** **145.4** **​** ​ 409.2 **​** **(64)** ​ |
| Global Healthcare and Life Sciences | **​** | **​** **65.6** **​** ​ ​ 31.2 **​** **​** **110** ​ | ​ | **​** **88.5** **​** ​ ​ 56.0 **​** **​** **58** ​ |
| Other |  | **​** **21.3** **​** ​ 41.8 **​** **(49)** ​ | ​ | **​** **42.9** **​** ​ 67.5 **​** **(36)** ​ |
| Corporate |  | **​** **(126.7)** **​** ​ (62.7) ​ ​ ​ ​ | ​ | **​** **(181.3)** **​** ​ (136.1) ​ ​ ​ ​ |
| Subtotal at fixed currency |  | **​** **206.2** **​** ​ 465.6 **​** **(56)** ​ | ​ | **​** **585.1** **​** ​ 778.9 **​** **(25)** ​ |
| Effect of foreign currency translation |  | **​** **(14.2)** **​** ​ (1.2) ​ ​ **​** ​ | ​ | **​** **(16.9)** **​** ​ (0.9) ​ ​ **​** ​ |
| Consolidated reported GAAP operating income |  | **$192.0** **​** ​ ​ $464.4 **​** **(59)%** | ​ | **$568.2** **​** ​ ​ $778.0 **​** **(27)%** |

The following tables reconcile the impact of acquisitions and divestitures within our reportable segments.

| ​ ​ ​ Net Sales (millions) | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Second Quarter Ended June 30 2020 ​ 2019 Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted ​ Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted |
| --- | --- | ---: |
| Global Industrial | **​** | **$1,475.6** **​** **$(8.7)** **​** **$1,466.9** ​ $1,500.7 ​ $(0.2) ​ $1,500.5 |
| Global Institutional |  | **722.4** **​** **(12.9)** **​** **709.5** ​ 1,112.5 ​ - ​ 1,112.5 |
| Global Healthcare and Life Sciences | **​** | **307.6** **​** **(5.8)** **​** **301.8** ​ 252.8 ​ (0.4) ​ 252.4 |
| Other |  | **247.1** **​** **(0.7)** **​** **246.4** ​ 306.2 ​ - ​ 306.2 |
| Corporate |  | **12.3** **​** **(12.3)** **​** **-** ​ - ​ - ​ - |
| Subtotal at fixed currency |  | **2,765.0** **​** **(40.4)** **​** **2,724.6** ​ 3,172.2 ​ (0.6) ​ 3,171.6 |
| Effect of foreign currency translation |  | **(79.3)** **​** ​ **​** ​ ​ (3.1) ​ ​ ​ ​ |
| Total reported net sales |  | **$2,685.7** **​** ​ **​** ​ ​ $3,169.1 ​ ​ ​ ​ |
| ​ | ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
| **Operating Income** | **​** | **2020** ​ 2019 |
| (millions) |  | Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted ​ Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted |
| Global Industrial | **​** | **$283.0** **​** **$(1.0)** **​** **$282.0** ​ $220.9 ​ $0.2 ​ $221.1 |
| Global Institutional |  | **(37.0)** **​** **(0.8)** **​** **(37.8)** ​ 234.4 ​ - ​ 234.4 |
| Global Healthcare and Life Sciences | **​** | **65.6** **​** **(0.1)** **​** **65.5** ​ 31.2 ​ - ​ 31.2 |
| Other |  | **21.3** **​** **(0.4)** **​** **20.9** ​ 41.8 ​ 0.1 ​ 41.9 |
| Corporate |  | **(30.3)** **​** **-** **​** **(30.3)** ​ (30.5) ​ - ​ (30.5) |
| Non-GAAP adjusted fixed currency operating income |  | **302.6** **​** **(2.3)** **​** **300.3** ​ 497.8 ​ 0.3 ​ 498.1 |
| Special (gains) and charges |  | **96.4** **​** **​** **​** **​** ​ 32.2 ​ ​ ​ ​ |
| Subtotal at fixed currency |  | **206.2** **​** **​** **​** **​** ​ 465.6 ​ ​ ​ ​ |
| Effect of foreign currency translation |  | **(14.2)** **​** **​** **​** **​** ​ (1.2) ​ ​ ​ ​ |
| Total reported operating income |  | **$192.0** **​** **​** **​** **​** ​ $464.4 ​ ​ ​ ​ |
| ​ | ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
| ​ | **​** | Six Months Ended |
| **​** | **​** | June 30 |
| **Net Sales** | **​** | **2020** ​ 2019 |
| (millions) |  | Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted ​ Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted |
| Global Industrial | **​** | **$2,919.2** **​** **(8.8)** **​** **$2,910.4** ​ $2,897.7 ​ (0.7) ​ $2,897.0 |
| Global Institutional |  | **1,794.5** **​** **(27.1)** **​** **1,767.4** ​ 2,132.7 ​ - ​ 2,132.7 |
| Global Healthcare and Life Sciences | **​** | **554.1** **​** **(15.4)** **​** **538.7** ​ 479.8 ​ (0.4) ​ 479.4 |
| Other | **​** | **524.7** **​** **(1.1)** **​** **523.6** ​ 580.9 ​ (0.1) ​ 580.8 |
| Corporate |  | **12.3** **​** **(12.3)** **​** **-** ​ - ​ - ​ - |
| Subtotal at fixed currency |  | **5,804.8** **​** **(64.7)** **​** **5,740.1** ​ 6,091.1 ​ (1.2) ​ 6,089.9 |
| Effect of foreign currency translation |  | **(98.5)** **​** ​ **​** ​ ​ 2.7 ​ ​ ​ ​ |
| Total reported net sales |  | **$5,706.3** **​** ​ **​** ​ ​ $6,093.8 ​ ​ ​ ​ |
| ​ | ​ | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ |
| **Operating Income** | **​** | **2020** ​ 2019 |
| (millions) |  | Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted ​ Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted |
| Global Industrial | **​** | **$489.6** **​** **(1.0)** **​** **$488.6** ​ $382.3 ​ 0.1 ​ $382.4 |
| Global Institutional |  | **145.4** **​** **(1.5)** **​** **143.9** ​ 409.2 ​ - ​ 409.2 |
| Global Healthcare and Life Sciences |  | **88.5** **​** **0.6** **​** **89.1** ​ 56.0 ​ - ​ 56.0 |
| Other | **​** | **42.9** **​** **(0.1)** **​** **42.8** ​ 67.5 ​ 0.1 ​ 67.6 |
| Corporate |  | **(59.9)** **​** **-** **​** **(59.9)** ​ (60.8) ​ - ​ (60.8) |
| Non-GAAP adjusted fixed currency operating income |  | **706.5** **​** **(2.0)** **​** **704.5** ​ 854.2 ​ 0.2 ​ 854.4 |
| Special (gains) and charges |  | **121.4** **​** **​** **​** **​** ​ 75.3 ​ ​ ​ ​ |
| Subtotal at fixed currency |  | **585.1** **​** **​** **​** **​** ​ 778.9 ​ ​ ​ ​ |
| Effect of foreign currency translation |  | **(16.9)** **​** **​** **​** **​** ​ (0.9) ​ ​ ​ ​ |
| Total reported operating income |  | **$568.2** **​** **​** **​** **​** ​ $778.0 ​ ​ ​ ​ |

44

Unless otherwise noted, the following segment performance commentary compares the second quarter and first six months of 2020 against the second quarter and first six months of 2019.

### Global Industrial

| ​ ​ ​ ​ | ​ ​ ​ | ​ Second Quarter Ended June 30 2020 | ​ ​ | ​ ​ | ​ 2019 | ​ ​ | ​ ​ ​ | ​ Six Months Ended June 30 2020 | ​ ​ | ​ ​ | ​ 2019 | ​ ​ | ​ ​ ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | --- | --- | ---: | --- | --- | --- | --- |
| Sales at fixed currency (millions) | **​** | **​** | **$1,475.6** ​ | ​ | ​ | $1,500.7 ​ | **​** | **​** | **$2,919.2** ​ | ​ | ​ | $2,897.7 ​ | ​ |
| Sales at public currency (millions) | **​** | **​** | **1,425.2** ​ | ​ | ​ | 1,501.0 ​ | **​** | **​** | **2,859.2** ​ | ​ | ​ | 2,902.2 ​ | ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ |
| Volume | **​** |  | **(4)%** | **​** |  | ​ ​ | **​** |  | **(1)%** | **​** |  | ​ ​ | ​ |
| Price changes | **​** |  | **2%** | **​** |  | ​ ​ | **​** |  | **2%** | **​** |  | ​ ​ | ​ |
| Acquisition adjusted fixed currency sales change | **​** | **​** | **(2)%** | **​** | ​ | ​ ​ | **​** | **​** | **0%** | **​** | ​ | ​ ​ | ​ |
| Acquisitions and divestitures | **​** |  | **1%** | **​** |  | ​ ​ | **​** |  | **0%** | **​** |  | ​ ​ | ​ |
| Fixed currency sales change | **​** |  | **(2)%** | **​** |  | ​ ​ | **​** |  | **1%** | **​** |  | ​ ​ | ​ |
| Foreign currency translation | **​** | **​** | **(3)%** | **​** | ​ | ​ ​ | **​** | **​** | **(2)%** | **​** | ​ | ​ ​ | ​ |
| Public currency sales change | **​** |  | **(5)%** | **​** |  | ​ ​ | **​** |  | **(1)%** | **​** |  | ​ ​ | ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ |
| Operating income at fixed currency (millions) | **​** | **​** | **$283.0** ​ | ​ | ​ | $220.9 ​ | **​** | **​** | **$489.6** ​ | ​ | ​ | $382.3 ​ | ​ |
| Operating income at public currency (millions) | **​** | **​** | **272.3** ​ | ​ | ​ | 220.9 ​ | **​** | **​** | **477.1** ​ | ​ | ​ | 382.9 ​ | ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ |
| Fixed currency operating income change | **​** | **​** | **28%** | **​** | ​ | ​ ​ | **​** | **​** | **28%** | **​** | ​ | ​ ​ | ​ |
| Fixed currency operating income margin | **​** |  | **19.2%** | **​** |  | 14.7% | **​** |  | **16.8%** | **​** |  | 13.2% | ​ |
| Acquisition adjusted fixed currency operating income change | **​** |  | **28%** | **​** |  | ​ ​ | **​** |  | **28%** | **​** |  | ​ ​ | ​ |
| Acquisition adjusted fixed currency operating income margin | **​** |  | **19.2%** | **​** |  | 14.7% | **​** |  | **16.8%** | **​** |  | 13.2% | ​ |
| Public currency operating income change | ​ | ​ | **23%** | ​ | ​ | ​ ​ | ​ | ​ | **25%** | ​ | ​ | ​ ​ | ​ |
| ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ | ​ |

Percentages in the above table do not necessarily sum due to rounding.

### Net Sales

Fixed currency sales for Global Industrial decreased in the second quarter and first six months of 2020, as lower volume more than offset pricing. In the second quarter and first six months, declines in North America more than offset gains in other regions.

At an operating segment level, ***Water*** fixed currency sales decreased 5% in the second quarter of 2020 and 2% in the first six months of 2020. Globally, our light industry water treatment sales declined modestly as gains in commercial building accounts were more than offset by the impact of plant closures at transportation customers in the quarter. Heavy industry sales declined moderately as the COVID-19 pandemic impact on primary metals and chemical production hurt sales. Mining declined modestly as gains in precious metals and fertilizers were more than offset by weak coal and alumina markets. ***Food & Beverage*** fixed currency sales increased 5% in both the second quarter of 2020 and in the first six months of 2020, led by new business wins and pricing. Globally, we saw strong growth in food with modest gains in dairy and protein. Beverage and brewing businesses declined. ***Downstream*** fixed currency sales decreased 9% in the second quarter of 2020 and 2% in the first six months of 2020 as steady petrochemical demand was more than offset by the negative impact of lower global transportation fuel demand on refineries. ***Paper*** fixed currency sales were flat in the second quarter of 2020 and increased 1% in the first six months of 2020, as new business generation and good trends in packaging and tissue were offset by graphic paper declines.

### Operating Income

Fixed currency operating income and fixed currency operating income margins increased for Global Industrial in the second quarter and first six months of 2020.

Acquisition adjusted fixed currency operating income margins increased 4.5 and 3.6 percentage points during the second quarter and first six months of 2020, respectively, and were positively impacted approximately 4.9 and 3.5 percentage points by lower discretionary spending, pricing and cost savings initiatives, which more than offset the 0.5 and 0.2 percentage point negative impact of lower volume during the second quarter and first six months of 2020, respectively.

### Global Institutional

| ​ ​ ​ ​ | ​ ​ ​ | ​ Second Quarter Ended June 30 2020 | ​ ​ | ​ ​ | ​ 2019 | ​ ​ | ​ ​ ​ | ​ Six Months Ended June 30 2020 | ​ ​ | ​ ​ | ​ 2019 | ​ ​ | ​ ​ ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | --- | --- | ---: | --- | --- | --- | --- |
| Sales at fixed currency (millions) | **​** | **​** | **$722.4** ​ | ​ | ​ | $1,112.5 ​ | **​** | **​** | **$1,794.5** ​ | ​ | ​ | $2,132.7 ​ | ​ |
| Sales at public currency (millions) | **​** | **​** | **708.1** ​ | ​ | ​ | 1,110.4 ​ | **​** | **​** | **1,775.1** ​ | ​ | ​ | 2,131.2 ​ | ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ |
| Volume | **​** |  | **(38)%** | **​** |  | ​ ​ | **​** |  | **(18)%** | **​** |  | ​ ​ | ​ |
| Price changes | **​** |  | **2%** | **​** |  | ​ ​ | **​** |  | **2%** | **​** |  | ​ ​ | ​ |
| Acquisition adjusted fixed currency sales change | **​** | **​** | **(36)%** | **​** | ​ | ​ ​ | **​** | **​** | **(17)%** | **​** | ​ | ​ ​ | ​ |
| Acquisitions and divestitures | **​** |  | **1%** | **​** |  | ​ ​ | **​** |  | **1%** | **​** |  | ​ ​ | ​ |
| Fixed currency sales change | **​** |  | **(35)%** | **​** |  | ​ ​ | **​** |  | **(16)%** | **​** |  | ​ ​ | ​ |
| Foreign currency translation | **​** | **​** | **(1)%** | **​** | ​ | ​ ​ | **​** | **​** | **(1)%** | **​** | ​ | ​ ​ | ​ |
| Public currency sales change | **​** |  | **(36)%** | **​** |  | ​ ​ | **​** |  | **(17)%** | **​** |  | ​ ​ | ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ |
| Operating income at fixed currency (millions) | **​** | **​** | **$(37.0)** ​ | ​ | ​ | $234.4 ​ | **​** | **​** | **$145.4** ​ | ​ | ​ | $409.2 ​ | ​ |
| Operating income at public currency (millions) | **​** | **​** | **(37.8)** ​ | ​ | ​ | 233.6 ​ | **​** | **​** | **143.9** ​ | ​ | ​ | 408.2 ​ | ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ |
| Fixed currency operating income change | **​** | **​** | **(116)%** | **​** | ​ | ​ ​ | **​** | **​** | **(64)%** | **​** | ​ | ​ ​ | ​ |
| Fixed currency operating income margin | **​** |  | **(5.1)%** | **​** |  | 21.1% | **​** |  | **8.1%** | **​** |  | 19.2% | ​ |
| Acquisition adjusted fixed currency operating income change | **​** |  | **(116)%** | **​** |  | ​ ​ | **​** |  | **(65)%** | **​** |  | ​ ​ | ​ |
| Acquisition adjusted fixed currency operating income margin | **​** |  | **(5.3)%** | **​** |  | 21.1% | **​** |  | **8.1%** | **​** |  | 19.2% | ​ |
| Public currency operating income change | ​ | ​ | **(116)%** | ​ | ​ | ​ ​ | ​ | ​ | **(65)%** | ​ | ​ | ​ ​ | ​ |
| ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ | ​ |

Percentages in the above table do not necessarily sum due to rounding.

### Net Sales

Fixed currency sales for Global Institutional decreased in the second quarter and first six months of 2020, driven by a decline in the Institutional business. At a regional level, the second quarter and first six months of 2020 fixed currency sales decreased in all major regions.

At an operating segment level, ***Institutional*** fixed currency sales decreased 50% and 26% in the second quarter and first six months of 2020, respectively, reflecting strong hand and surface hygiene sales that were more than offset by mandated reductions for in-unit dining and domestic and international travel that significantly impacted foot traffic at full-service restaurants, occupancy rates at hotels and a reduction of customer visits to other entertainment facilities through the quarter. In addition, distributors reduced inventories in the second quarter of 2020. All regions showed significant declines. ***Specialty*** fixed currency sales increased 15% (9% acquisition adjusted) and 17% (12% acquisition adjusted) in the second quarter and first six months of 2020, respectively, led by very strong demand in the food retail sector, which more than offset modest declines in quickservice sales due to customer store closures in International markets, the slow return to dine-in in North America and some inventory destocking following the initial surge of cleaning and sanitizing orders in the first quarter.

### Operating Income

Fixed currency operating income and fixed currency operating income margins decreased for our Global Institutional segment in the second quarter and first six months of 2020.

Acquisition adjusted fixed currency operating income margins decreased 26.4 and 11.1 percentage points during the second quarter and first six months of 2020, respectively. Margins were negatively impacted approximately 30.4 and 13.4 percentage points in the second quarter and first six months of 2020, respectively, from significant volume declines, reduced operating leverage, unfavorable mix and higher bad debt, which more than offset the 4.4 percentage point positive impact from lower discretionary spending and cost savings initiatives during the second quarter of 2020, and the 2.8 percentage point positive impact from improved pricing and cost savings initiatives during the first six months of 2020.

### Global Healthcare and Life Sciences

| ​ ​ ​ ​ | ​ ​ ​ | ​ Second Quarter Ended June 30 2020 | ​ ​ | ​ ​ | ​ 2019 | ​ ​ | ​ ​ ​ ​ | ​ Six Months Ended June 30 2020 | ​ ​ | ​ ​ | ​ 2019 | ​ ​ | ​ ​ ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | --- | --- | ---: | --- | --- | --- | --- |
| Sales at fixed currency (millions) | **​** | **​** | **$307.6** ​ | ​ | ​ | $252.8 ​ | ​ | **​** | **$554.1** ​ | ​ | ​ | $479.8 ​ | ​ |
| Sales at public currency (millions) | **​** | **​** | **298.5** ​ | ​ | ​ | 251.9 ​ | ​ | **​** | **542.3** ​ | ​ | ​ | 479.4 ​ | ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ |
| Volume | **​** |  | **18%** | **​** |  | ​ ​ | ​ |  | **11%** | **​** |  | ​ ​ | ​ |
| Price changes | **​** |  | **1%** | **​** |  | ​ ​ | ​ |  | **1%** | **​** |  | ​ ​ | ​ |
| Acquisition adjusted fixed currency sales change | **​** | **​** | **20%** | **​** | ​ | ​ ​ | ​ | **​** | **12%** | **​** | ​ | ​ ​ | ​ |
| Acquisitions and divestitures | **​** |  | **2%** | **​** |  | ​ ​ | ​ |  | **3%** | **​** |  | ​ ​ | ​ |
| Fixed currency sales change | **​** |  | **22%** | **​** |  | ​ ​ | ​ |  | **15%** | **​** |  | ​ ​ | ​ |
| Foreign currency translation | **​** | **​** | **(3)%** | **​** | ​ | ​ ​ | ​ | **​** | **(2)%** | **​** | ​ | ​ ​ | ​ |
| Public currency sales change | **​** |  | **18%** | **​** |  | ​ ​ | ​ |  | **13%** | **​** |  | ​ ​ | ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ |
| Operating income at fixed currency (millions) | **​** | **​** | **$65.6** ​ | ​ | ​ | $31.2 ​ | ​ | **​** | **$88.5** ​ | ​ | ​ | $56.0 ​ | ​ |
| Operating income at public currency (millions) | **​** | **​** | **63.0** ​ | ​ | ​ | 31.0 ​ | ​ | **​** | **85.5** ​ | ​ | ​ | 55.8 ​ | ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ |
| Fixed currency operating income change | **​** | **​** | **110%** | **​** | ​ | ​ ​ | ​ | **​** | **58%** | **​** | ​ | ​ ​ | ​ |
| Fixed currency operating income margin | **​** |  | **21.3%** | **​** |  | 12.3% | ​ |  | **16.0%** | **​** |  | 11.7% | ​ |
| Acquisition adjusted fixed currency operating income change | **​** |  | **110%** | **​** |  | ​ ​ | ​ |  | **59%** | **​** |  | ​ ​ | ​ |
| Acquisition adjusted fixed currency operating income margin | **​** |  | **21.7%** | **​** |  | 12.4% | ​ |  | **16.5%** | **​** |  | 11.7% | ​ |
| Public currency operating income change | ​ | ​ | **103%** | ​ | ​ | ​ ​ | ​ | ​ | **53%** | ​ | ​ | ​ ​ | ​ |
| ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ | ​ |

Percentages in the above table do not necessarily sum due to rounding.

### Net Sales

Fixed currency sales for Global Healthcare and Life Sciences increased in the second quarter and first six months of 2020, driven by volume gains. At a regional level, the second quarter and first six months of 2020 fixed currency sales increased in all regions.

At an operating segment level, ***Healthcare*** fixed currency sales increased 15% (12% acquisition adjusted) and 11% (7% acquisition adjusted) in the second quarter and first six months of 2020, respectively, as strong COVID-19 pandemic-related hand and surface disinfection sales growth more than offset the unfavorable effects of delayed elective surgical procedures. ***Life Sciences*** fixed currency sales increased 52% (53% acquisition adjusted) and 39% (36% acquisition adjusted) in the second quarter and first six months of 2020, respectively, driven by significant demand for our Bioquell biodecontamination systems due to COVID-19 pandemic concerns, business wins and an apparent moderate inventory build by customers.

### Operating Income

Fixed currency operating income and fixed currency operating income margins for our Global Healthcare and Life Sciences segment increased in the second quarter and first six months of 2020.

Acquisition adjusted fixed currency operating income margins increased 9.3 and 4.8 percentage points during the second quarter and first six months of 2020, respectively. Strong volume gains, favorable mix, lower discretionary spending and improved pricing impacted margins by approximately 9.3 and 5.8 percentage points during the second quarter and first six months of 2020, respectively, which more than offset reduced operating leverage and lower efficiency due to the Healthcare product recall remediation which negatively impacted margins by 0.5 percentage points during the first six months of 2020.

### Other

| ​ ​ ​ ​ | ​ ​ ​ | ​ Second Quarter Ended June 30 2020 | ​ ​ | ​ ​ | ​ 2019 | ​ ​ | ​ ​ ​ | ​ Six Months Ended June 30 2020 | ​ ​ | ​ ​ | ​ 2019 | ​ ​ | ​ ​ ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | --- | --- | ---: | --- | --- | --- | --- |
| Sales at fixed currency (millions) | **​** | **​** | **$247.1** ​ | ​ | ​ | $306.2 ​ | **​** | **​** | **$524.7** ​ | ​ | ​ | $580.9 ​ | ​ |
| Sales at public currency (millions) | **​** | **​** | **241.6** ​ | ​ | ​ | 305.8 ​ | **​** | **​** | **517.4** ​ | ​ | ​ | 581.0 ​ | ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ |
| Volume | **​** |  | **(21)%** | **​** |  | ​ ​ | **​** |  | **(11)%** | **​** |  | ​ ​ | ​ |
| Price changes | **​** |  | **2%** | **​** |  | ​ ​ | **​** |  | **2%** | **​** |  | ​ ​ | ​ |
| Acquisition adjusted fixed currency sales change | **​** | **​** | **(20)%** | **​** | ​ | ​ ​ | **​** | **​** | **(10)%** | **​** | ​ | ​ ​ | ​ |
| Acquisitions and divestitures | **​** |  | **0%** | **​** |  | ​ ​ | **​** |  | **0%** | **​** |  | ​ ​ | ​ |
| Fixed currency sales change | **​** |  | **(19)%** | **​** |  | ​ ​ | **​** |  | **(10)%** | **​** |  | ​ ​ | ​ |
| Foreign currency translation | **​** | **​** | **(2)%** | **​** | ​ | ​ ​ | **​** | **​** | **(1)%** | **​** | ​ | ​ ​ | ​ |
| Public currency sales change | **​** |  | **(21)%** | **​** |  | ​ ​ | **​** |  | **(11)%** | **​** |  | ​ ​ | ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ |
| Operating income at fixed currency (millions) | **​** | **​** | **$21.3** ​ | ​ | ​ | $41.8 ​ | **​** | **​** | **$42.9** ​ | ​ | ​ | $67.5 ​ | ​ |
| Operating income at public currency (millions) | **​** | **​** | **20.8** ​ | ​ | ​ | 41.8 ​ | **​** | **​** | **42.4** ​ | ​ | ​ | 67.5 ​ | ​ |
| ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | **​** | **​** | **​** ​ | ​ | ​ | ​ ​ | ​ |
| Fixed currency operating income change | **​** | **​** | **(49)%** | **​** | ​ | ​ ​ | **​** | **​** | **(36)%** | **​** | ​ | ​ ​ | ​ |
| Fixed currency operating income margin | **​** |  | **8.6%** | **​** |  | 13.7% | **​** |  | **8.2%** | **​** |  | 11.6% | ​ |
| Acquisition adjusted fixed currency operating income change | **​** |  | **(50)%** | **​** |  | ​ ​ | **​** |  | **(37)%** | **​** |  | ​ ​ | ​ |
| Acquisition adjusted fixed currency operating income margin | **​** |  | **8.5%** | **​** |  | 13.7% | **​** |  | **8.2%** | **​** |  | 11.6% | ​ |
| Public currency operating income change | ​ | ​ | **(50)%** | ​ | ​ | ​ ​ | ​ | ​ | **(37)%** | ​ | ​ | ​ ​ | ​ |
| ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ | ​ | ​ | **​** **​** | ​ | ​ | ​ ​ | ​ |

Percentages in the above table do not necessarily sum due to rounding.

### Net Sales

Fixed currency sales for Other decreased in the second quarter and first six months of 2020 due to the impact of COVID-19 on partial and full customer closures along with limited vendor access. At a regional level, the second quarter and first six months of 2020 sales results impacted North America and Europe.

At an operating segment level, ***Pest Elimination*** fixed currency sales decreased 10% and 5% in the second quarter and first six months of 2020, respectively. Sales results reflect the partial and full customer closures along with limited vendor access policies due to pandemic restrictions hurt Pest Elimination service delivery and sales in North America and Europe through the quarter. ***Colloidal Technologies Group*** fixed currency sales decreased 22% and 12% in the second quarter and first six months of 2020, respectively. ***Textile Care*** fixed currency sales decreased 44% and 24% in the second quarter and first six months of 2020, respectively.

### Operating Income

Acquisition adjusted fixed currency operating income margins for Other decreased 5.2 and 3.4 percentage points during the second quarter and first six months of 2020, respectively. Lower volume, reduced operating leverage and unfavorable mix negatively impacted margins by approximately 8.5 and 6.1 percentage points for the second quarter and first six months of 2020, respectively. These margin declines were partially offset by lower discretionary spending, improved pricing and cost savings initiatives which positively impacted margins by approximately 4.1 and 3.2 percentage points for the second quarter and first six months of 2020, respectively.

### Corporate

Consistent with our internal management reporting, Corporate amounts in the table on page 43 include sales to ChampionX in accordance with the long-term supply agreement entered into with the Transaction post-separation, as discussed in Note 4, intangible asset amortization specifically from the Nalco merger and special (gains) and charges that are not allocated to our reportable segments. Items included within special (gains) and charges are shown in the table on page 39.

### FINANCIAL POSITION, CASH FLOWS AND LIQUIDITY

### Financial Position

Total assets were $18.1 billion as of June 30, 2020 compared to total assets of $20.9 billion as of December 31, 2019. The decrease in total assets reflects the separation of ChampionX.

Total liabilities were $12.2 billion as of June 30, 2020 compared to total liabilities of $12.1 billion as of December 31, 2019. Total debt was $7.3 billion as of June 30, 2020 and $6.4 billion as of December 31, 2019. See further discussion of our debt activity within the “Liquidity and Capital Resources” section of this MD&A.

Our net debt to earnings before interest, taxes, depreciation and amortization (“EBITDA”) is shown in the following table. EBITDA is a non-GAAP measures discussed further in the “Non-GAAP Financial Measures” section of this MD&A.

The inputs to EBITDA reflect the trailing twelve months of activity for the period presented.

| ​ ​ (ratio) | ​ ​ | ​ 2020 ​ | ​ ​ | ​ ​ | ​ ​ | ​ 2019 ​ | ​ ​ | ​ ​ | ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- |
| Net debt to EBITDA |  | **​** | **2.4** | **​** |  | ​ | 2.7 | ​ |  |
| ​ | **​** | **​** | **​** | **​** | ​ | ​ | ​ | ​ | **​** |
| (millions) |  | **​** | **​** | **​** | ​ | ​ | ​ | ​ |  |
| Total debt | **​** | **​** | **$7,286.9** | **​** | ​ | ​ | $7,056.1 | ​ | **​** |
| Cash | **​** |  | **1,369.0** | **​** | ​ | ​ | 15.7 | ​ | **​** |
| Net debt | **​** | **​** | **$5,917.9** | **​** | ​ | ​ | $7,040.4 | ​ | **​** |
| ​ | **​** | **​** | **​** | **​** | ​ | ​ | ​ | ​ | **​** |
| Net income including noncontrolling interest | ​ | **​** | **$1,270.5** | **​** | ​ | ​ | $1,333.1 | ​ | ​ |
| Provision for income taxes | **​** |  | **231.1** | **​** | ​ | ​ | 301.1 | ​ | **​** |
| Interest expense, net | **​** |  | **199.1** | **​** | ​ | ​ | 207.5 | ​ | **​** |
| Depreciation | **​** |  | **580.8** | **​** | ​ | ​ | 554.0 | ​ | **​** |
| Amortization | **​** |  | **205.9** | **​** | ​ | ​ | 199.5 | ​ | **​** |
| EBITDA | **​** |  | **$2,487.4** | **​** | ​ | ​ | $2,595.2 | ​ | **​** |
| ​ | **​** | **​** | **​** | **​** | ​ | ​ | ​ | ​ | **​** |

### Cash Flows

### Operating Activities

| ​ ​ ​ (millions) | ​ ​ ​ | ​ Six Months Ended June 30 2020 | ​ | ​ | ​ ​ | ​ 2019 | ​ | ​ | ​ | ​ Change | ​ | ​ | ​ ​ ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- |
| Cash provided by operating activities | ​ | **​** | **$640.2** | ​ | ​ | ​ | $764.3 | ​ | ​ | **​** | **$(124.1)** | **​** | **​** |

We continue to generate cash flow from operations, amidst the COVID-19 pandemic, allowing us to fund our ongoing operations, acquisitions, investments in the business and pension obligations along with returning cash to our shareholders through dividend payments and share repurchases. Cash provided by operating activities decreased $124 million in the first six months of 2020 compared to the first six months of 2019, driven primarily by a $172 million reduction in net income from continuing operations including noncontrolling interest and $40 million in net cash payment for restructuring, partially offset by $67 million due to favorable fluctuations in accounts receivable, inventories and accounts payable (“working capital”). The cash flow impact from working capital accounts was driven by lower sales volume, partially offset by lower accounts receivable and inventory turnover.

### Investing Activities

| ​ ​ ​ (millions) | ​ ​ ​ | ​ Six Months Ended June 30 2020 | ​ | ​ | ​ ​ | ​ 2019 | ​ | ​ | ​ | ​ Change | ​ | ​ | ​ ​ ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- |
| Cash used for investing activities | ​ | **​** | **$(689.7)** | ​ | ​ | ​ | $(623.9) | ​ | ​ | **​** | **$(65.8)** | **​** | **​** |

49

Cash used for investing activities is primarily impacted by the timing of business acquisitions and dispositions as well as capital investments in the business.

Total cash paid for acquisitions, net of cash acquired along with net cash received from dispositions, during the first six months of 2020 and 2019, was $431 million and $288 million, respectively. Our acquisitions and divestitures are discussed further in Note 3. We continue to target strategic business acquisitions which complement our growth strategy and expect to continue to make capital investments and acquisitions in the future to support our long-term growth.

We continue to make capital investments in the business, including merchandising and customer equipment and manufacturing facilities. Total capital expenditures were $251 million and $341 million in the second quarter of 2020 and 2019, respectively.

### Financing Activities

| ​ ​ ​ (millions) | ​ ​ ​ | ​ Six Months Ended June 30 2020 | ​ | ​ | ​ ​ | ​ 2019 | ​ | ​ | ​ | ​ Change | ​ | ​ | ​ ​ ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- |
| Cash provided by (used for) financing activities | ​ | **​** | **$720.6** | ​ | ​ | ​ | $(473.7) | ​ | ​ | **​** | **$1,194.3** | **​** | **​** |

Our cash flows from financing activities primarily reflect the issuances and repayment of debt, common stock repurchases, proceeds from common stock issuances related to our equity incentive programs and dividend payments.

We issued $750 million par value and received $769 million in proceeds of long-term debt in the first six months of 2020. We repaid $300 million and $400 million of long-term debt in the first six months of 2020 and 2019, respectively. The proceeds received from the debt issuances will be used for repayment of commercial paper and general corporate purposes. In addition, we had net issuances of commercial paper of $454 million and $434 million in the second quarter of 2020 and 2019, respectively.

Shares are repurchased for the purpose of partially offsetting the dilutive effect of our equity compensation plans and stock issued in acquisitions, to manage our capital structure and to efficiently return capital to shareholders. We repurchased a total of $105 million and $348 million of shares in the first six months of 2020 and 2019, respectively. Cash proceeds and tax benefits from stock option exercises provide a portion of the funding for repurchase activity.

The impact on financing cash flows of commercial paper and notes payable issuances and long-term debt borrowings and repayments are shown in the following table:

| ​ ​ ​ (millions) | ​ ​ ​ ​ | ​ Six Months Ended June 30 2020 | ​ | ​ | ​ ​ | ​ 2019 | ​ | ​ | ​ | ​ Change | ​ | ​ | ​ ​ ​ ​ |
| --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- | --- | ---: | --- | --- |
| Net issuances of commercial paper and notes payable | **​** | **​** | **$454.4** | ​ | ​ | ​ | $434.4 | ​ | ​ | **​** | **$20.0** | ​ | ​ |
| Long-term debt borrowings | **​** | **​** | **768.9** | ​ | ​ | ​ | - | ​ | ​ | **​** | **768.9** | ​ | ​ |
| Long-term debt repayments | **​** | **​** | **(300.0)** | ​ | ​ | ​ | (400.0) | ​ | ​ | **​** | **100.0** | ​ | ​ |

### Liquidity and Capital Resources

We currently expect to fund the cash requirements which are reasonably foreseeable for the next twelve months, including scheduled debt repayments, new investments in the business, share repurchases, dividend payments, possible business acquisitions and pension and postretirement contributions with cash from operating activities, and as needed, additional short-term and/or long-term borrowings. We continue to expect our operating cash flow to remain strong.

As of June 30, 2020, we had $1,369 million of cash and cash equivalents on hand, of which $194 million was held outside of the U.S. We have increased our available cash on hand during the second quarter to meet current and any future potential operational cash needs as a result of COVID-19 pandemic. We will continue to evaluate our cash position in light of future developments.

As of June 30, 2020, we have a $2.0 billion multi-year credit facility which expires in November 2022. The credit facility has been established with a diverse syndicate of banks and supports our U.S. and Euro commercial paper programs. The maximum aggregate amount of commercial paper that may be issued under our U.S. commercial paper program and our Euro commercial paper program may not exceed $2.0 billion. At the end of the second quarter of 2020, we had $314 million (€283 million) of commercial paper outstanding under our Euro program and $203 million outstanding under our U.S. program. There were no borrowings under our credit facility as of June 30, 2020 or 2019. As of June 30, 2020, both programs were rated A-2 by Standard & Poor’s, P-2 by Moody’s and F-1 by Fitch.

As of June 30, 2020, we have a $500 million 364-day revolving credit agreement to be used for general corporate purposes with a diverse syndicate of banks to provide for further liquidity over the next twelve months in response to the coronavirus pandemic. There were no borrowings under this revolving credit agreement as of June 30, 2020. In addition, we executed a $305 million term credit agreement in April 2020, which we drew on and repaid $303 million during the second quarter of 2020.

Our long-term debt issuance and repayment activity through the first six months of 2020 and 2019 is discussed in the Cash Flows – Financing Activities section of this MD&A.

We are in compliance with our debt covenants and believe we have sufficient borrowing capacity to meet our foreseeable operating activities, as needed.

The schedule of contractual obligations included in the Financial Position and Liquidity section of our Form 10-K for the year ended December 31, 2019 disclosed total notes payable and long-term debt due within one year of $326 million. As of June 30, 2020, the total notes payable and long-term debt due within one year decreased to $18 million. The commercial paper outstanding as of June 30, 2020 increased to $517 million. The commercial paper outstanding as of December 31, 2019 was $55 million.

Our gross liability for uncertain tax positions was $26 million as of June 30, 2020 and $28 million as of December 31, 2019. We are not able to reasonably estimate the amount by which the liability will increase or decrease over time; however, at this time, we do not expect significant payments related to these obligations within the next year.

### GLOBAL ECONOMIC ENVIRONMENT

### Coronavirus disease 2019 (COVID-19)

In March 2020, the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization. The COVID-19 pandemic is continuing to affect major economic and financial markets, while industries are facing the challenges with the economic conditions resulting from efforts to address the pandemic. As the spread of the pandemic continues, many countries have required companies to limit or suspend business operations and have implemented travel restrictions. These conditions have had and will continue to have a negative impact on market conditions and customer demand throughout the world. We anticipate continued adverse impacts and disruptions in our restaurant, hospitality and entertainment-related business operations, with modest impact on our Industrial segment businesses and limited or no adverse impacts on certain other parts of our business, supply chain and business continuity plans from COVID-19 restrictions; certain of our business will benefit from increased cleaning and sanitizing product demand. The ongoing effects of the global COVID-19 outbreak could result in a global recession.

We anticipate a reduction to our 2020 results of operations and operating cash flows versus prior year levels due to lower market demand, but we are not yet able to estimate the full impact of the coronavirus outbreak as it continues to spread globally. While we continue to provide cleaning, disinfection programs and increased sanitizing protocols in response to the COVID-19 pandemic in healthcare, quick-service and food and beverage plant customers, we anticipate products and services provided to the full-service restaurant, hospitality, lodging and entertainment industries will continue to be negatively impacted in the upcoming quarter due to the regulatory and organizational mandates that have been put in place. We have taken, and are continuing to take, steps to reduce costs, including reductions in capital expenditures, as well as other ongoing cost initiatives.

### Global Economies

Approximately half of our sales are outside of the U.S. Our international operations subject us to changes in economic conditions and foreign currency exchange rates as well as political uncertainty in some countries which could impact future operating results.

Argentina has continued to experience negative economic trends, evidenced by multiple periods of increasing inflation rates, devaluation of the peso, and increasing borrowing rates. Argentina is classified as a highly inflationary economy in accordance with U.S. GAAP, and the U.S. dollar is the functional currency for our subsidiaries in Argentina. During the first six months of 2020, sales in Argentina represented less than 1% of our consolidated sales. Assets held in Argentina at the end of the second quarter represented less than 1% of our consolidated assets.

### Brexit Referendum

Effective January 31, 2020, the U.K. left the European Union. The U.K.’s relationship with the EU will no longer be governed by the EU Treaties, but instead by the terms of the Withdrawal Agreement agreed between the U.K. and the EU in late 2019. The Withdrawal Agreement provides for a “transition” period, which commenced the moment the U.K. left the EU and is currently set to end on December 31, 2020. At the end of the transition period, there may be significant changes to the U.K.’s business environment. While the effects of Brexit will depend on any agreements the U.K. makes to retain access to EU markets or the failure to reach such agreements, the uncertainties created by Brexit, any resolution between the U.K. and EU countries or the failure to reach any such resolutions, could adversely affect our relationships with customers, suppliers and employees and could adversely affect our business.

### NEW ACCOUNTING PRONOUNCEMENTS

For information on new accounting pronouncements, refer to Note 18 to the Consolidated Financial Statements.

### NON-GAAP FINANCIAL MEASURES

This Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Item 2, contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). These non-GAAP measures include:

- Fixed currency sales
- Acquisition adjusted fixed currency sales
- Adjusted cost of sales
- Adjusted gross margin
- Fixed currency operating income
- Fixed currency operating income margin
- Adjusted operating income
- Adjusted operating income margin
- Adjusted fixed currency operating income
- Adjusted fixed currency operating income margin
- Acquisition adjusted fixed currency operating income
- Acquisition adjusted fixed currency operating income margin
- Adjusted interest expense, net
- EBITDA
- Adjusted tax rate
- Adjusted net income attributable to Ecolab
- Adjusted diluted EPS

We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results.

Our non-GAAP financial measures for cost of sales, gross margin and operating income exclude the impact of special (gains) and charges, and our non-GAAP measures for tax rate, net income attributable to Ecolab and diluted EPS further exclude the impact of discrete tax items. We include items within special (gains) and charges and discrete tax items that we believe can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results. After tax special (gains) and charges are derived by applying the applicable local jurisdictional tax rate to the corresponding pre-tax special (gains) and charges.

EBITDA is defined as the sum of net income including noncontrolling interest, provision for income taxes, net interest expense, depreciation and amortization. EBITDA is used in our net debt to EBITDA ratio, which we view as important indicators of the operational and financial health of our organization.

We evaluate the performance of our international operations based on fixed currency rates of foreign exchange. Fixed currency amounts included in this Form 10-Q are based on translation into U.S. dollars at the fixed foreign currency exchange rates established by management at the beginning of 2020.

Acquisition adjusted growth rates exclude the results of our acquired businesses from the first twelve months post acquisition, exclude the results of our divested businesses from the twelve months prior to divestiture.

These non-GAAP measures are not in accordance with, or an alternative to U.S. GAAP, and may be different from non-GAAP measures used by other companies. Investors should not rely on any single financial measure when evaluating our business. We recommend that investors view these measures in conjunction with the U.S. GAAP measures included in this MD&A and we have provided reconciliations of reported U.S. GAAP amounts to the non-GAAP amounts.

### FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 2, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include the effects of the COVID-19 pandemic; expectations concerning timing, amount and type of restructuring costs and savings from restructuring activities; tax deductibility of goodwill; capital investments and acquisitions; amortization expense; non-performance of financial counterparties; payments and contributions to pension and postretirement health care benefit plans; impact of tax reform; the impact of lawsuits, claims and environmental matters; impact of new accounting pronouncements; cash flows, borrowing capacity and funding of cash requirements; payments related to uncertain tax positions; and implementation of ERP system upgrade.

Without limiting the foregoing, words or phrases such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “we believe,” “we expect,” “estimate,” “project” (including the negative or variations thereof) or similar terminology, generally identify forward-looking statements. Forward-looking statements may also represent challenging goals for us. These statements, which represent our expectations or beliefs concerning various future events, are based on current expectations that involve a number of risks and uncertainties that could cause actual results to differ materially from those of such forward-looking statements. In particular, the effects of the COVID-19 pandemic depend on the duration of the outbreak, government response to the outbreak, the success of mitigation strategies, the ability of our customers to ramp up operations and the frequency of additional outbreaks; and the ultimate results of any restructuring and business improvement actions, including cost synergies, depend on a number of factors, including the development of final plans, the impact of local regulatory requirements regarding employee terminations, the time necessary to develop and implement the restructuring and other business improvement initiatives and the level of success achieved through such actions in improving competitiveness, efficiency and effectiveness. We caution that undue reliance should not be placed on such forward-looking statements, which speak only as of the date made.

Some of the factors which could cause results to differ materially from those expressed in any forward-looking statements are set forth under Item 1A of our most recent Form 10-K, and our other public filings with the Securities and Exchange Commission (the "SEC"), and include the effects of the coronavirus (COVID-19) pandemic; the vitality of the markets we serve; the impact of economic factors such as the worldwide economy, capital flows, interest rates, foreign currency risk and reduced sales and earnings in our international operations resulting from the weakening of local currencies versus the U.S. dollar; our ability to execute key business initiatives, including restructurings and our Enterprise Resource Planning system upgrades; potential information technology infrastructure failures or breaches in data security; our ability to attract, retain and develop high caliber management talent to lead our business; our ability to successfully compete with respect to value, innovation and customer support; exposure to global economic, political and legal risks related to our international operations; difficulty in procuring raw materials or fluctuations in raw material costs; pressure on operations from consolidation of customers or vendors; the costs and effects of complying with laws and regulations, including those relating to the environment, to the manufacture, storage, distribution, sale and use of our products and to labor and employment, as well as to the conduct of our business generally; the occurrence of litigation or claims, including class action lawsuits; restraints on pricing flexibility due to contractual obligations; our ability to acquire complementary businesses and to effectively integrate such businesses; changes in tax laws and unanticipated tax liabilities; potential loss of deferred tax assets; our indebtedness, and any failure to comply with the covenants that apply to our indebtedness; public health outbreaks, epidemics or pandemics, such as the current outbreak of COVID-19; potential losses arising from the impairment of goodwill or other assets; potential chemical spill or release; the loss or insolvency of a major customer or distributor; repeated or prolonged government and/or business shutdowns or similar events; acts of war or terrorism; natural or man-made disasters; water shortages; severe weather conditions; and other uncertainties or risks reported from time to time in our reports to the SEC. There can be no assurances that our earnings levels will meet investors’ expectations. Except as may be required under applicable law, we do not undertake, and expressly disclaim, any duty to update our Forward-Looking Statements.

## Market risk

As filed, 555 characters.

We use foreign currency forward contracts, interest rate swap agreements and foreign currency debt to manage risks associated with foreign currency exchange rates, interest rates and net investments in our foreign operations. We do not hold derivative financial instruments of a speculative nature or for trading purposes. For a more detailed discussion of derivative instruments, refer to Note 8, entitled “Derivatives and Hedging Transactions”, of the consolidated financial statements located under Part I, Item 1 of this quarterly report on Form 10-Q.

## Controls and procedures

As filed, 1,336 characters.

As of June 30, 2020, we carried out an evaluation, under the supervision and with the participation of our management, including the Chairman of the Board and Chief Executive Officer and the Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon that evaluation, our Chairman of the Board and Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures are effective.

During the period April 1 through June 30, 2020, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

We are continuing our implementation of our enterprise resource planning (“ERP”) system upgrades, which are expected to occur in phases over the next several years. These upgrades, which include supply chain and certain finance functions, are expected to improve the efficiency of certain financial and related transactional processes. We also made changes to our system in order to support our separation of the ChampionX business. These upgrades of the ERP systems will affect the processes that constitute our internal control over financial reporting and will require testing for effectiveness.

## Risk factors

As filed, 4,979 characters.

In our report on Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission on February 28, 2020, we identify under Item 1A important factors which could affect our financial performance and could cause our actual results for future periods to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statements made in this Form 10-Q. See the section entitled Forward-Looking Statements located on page 53 of this Form 10-Q. We may also refer to such disclosure to identify factors that may cause results to differ from those expressed in other forward-looking statements made in oral presentations, including telephone conferences and/or webcasts open to the public.

The discussion below provides updates and additions to the risk factors and should be read together with the full list of risk factors set forth in the Form 10-K.

***The COVID-19 pandemic has materially and adversely impacted, and we expect will continue to materially and adversely impact, our business.***

The COVID-19 pandemic has had a rapid and significant negative impact on the global economy, including a significant downturn in the foodservice, hospitality, and travel industries. Preventative measures taken to alleviate the pandemic (such as stay-at-home orders and other responsive measures) have significantly impacted our restaurant and hospitality customers and negatively affected demand for our products and services in these segments, resulting in a material adverse effect on our business and results of operations. Prolonged economic weakness, including an extended period of elevated levels of unemployment in the U.S., could further reduce discretionary consumer spending and consumer confidence, which could have a further adverse effect on our business and results of operations. We expect the full impact of the COVID-19 pandemic, including the extent of its effect on our business, results of operations and financial condition, to be dictated by future developments which remain uncertain and cannot be predicted, such as its duration and spread, the success of efforts to contain it, the possibility of subsequent widespread outbreaks, and the impact of actions taken in response. In addition to the reduction in the demand for our products and services, the COVID-19 pandemic has had, and we expect will continue to have, certain negative impacts on our business, including, but not limited to, the following:

- We rely on a global workforce, and our business demands we take measures to protect the health and safety of our employees, customers and others with whom we do business, while continuing to effectively manage our employees and maintain business operations. We have taken additional measures and incurred additional expenses to protect the health and safety of our employees to comply with applicable government requirements and safety guidance. Additionally, our business operations may be disrupted if a significant portion of our workforce is unable to work safely and effectively due to illness, quarantines, government actions, or other

restrictions or measures responsive to the pandemic, or if members of senior management or our Board of Directors are unable to perform their duties for an extended period of time. Measures taken across our business operations to address health and safety may not be sufficient to prevent the spread of COVID-19 among our employee base, customers and others. Therefore, we could face operational disruptions and incur additional expenses, including devoting additional resources to assisting employees diagnosed with COVID-19 and further changing health and safety protocols and processes, that could adversely affect our business and results of operations.

- A significant number of our employees as well as customers and others with whom we do business, continue to work remotely in response to the COVID-19 pandemic. Our business operations may be disrupted, and we may experience increased risk of adverse effects to our business, if a significant portion of our workforce or certain business operations are negatively impacted as a result of remote work arrangements, including due to cyber risks or other disruption to our technology infrastructure. Further, if our key operating facilities experience closures or worker shortages as a result of COVID-19, whether temporary or sustained, our business operations could be significantly disrupted.
- Cost management and various cost-containment actions implemented across our business in response to the COVID-19 pandemic could hinder execution of our business strategy, including deferral of planned capital expenditures, and could adversely affect our business and results of operations.
- We cannot be certain that loss or delay in the collection of accounts receivable will not have a material adverse effect on our results of operations and financial condition.

Filed Aug 6, 2020.
Source: SEC EDGAR, the filing index for accession 0001558370-20-009506. Last ingested by Listed: Nov 13, 2026, 16:24 ET. No prices; not investment advice.
